111 related articles for article (PubMed ID: 25437464)
1. [Safety and tolerability of GLP-1 receptor agonists].
Soldevila B; Puig-Domingo M
Med Clin (Barc); 2014 Sep; 143 Suppl 2():35-40. PubMed ID: 25437464
[TBL] [Abstract][Full Text] [Related]
2. [Safety and tolerability of GLP-1 receptor agonists].
Soldevila B; Puig-Domingo M
Med Clin (Barc); 2014; 143 Suppl 2():35-40. PubMed ID: 25326842
[TBL] [Abstract][Full Text] [Related]
3. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.
Aroda VR; Ratner R
Diabetes Metab Res Rev; 2011 Sep; 27(6):528-42. PubMed ID: 21484979
[TBL] [Abstract][Full Text] [Related]
4. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes.
Russell-Jones D
Int J Clin Pract; 2010 Sep; 64(10):1402-14. PubMed ID: 20716148
[TBL] [Abstract][Full Text] [Related]
5. [Modulation of the incretin effect in the treatment of diabetes].
Vidal J
Med Clin (Barc); 2014 Sep; 143 Suppl 2():8-11. PubMed ID: 25437459
[TBL] [Abstract][Full Text] [Related]
6. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
[TBL] [Abstract][Full Text] [Related]
7. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
8. An updated review on cancer risk associated with incretin mimetics and enhancers.
Tseng CH; Lee KY; Tseng FH
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
[TBL] [Abstract][Full Text] [Related]
9. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
Peterson G
Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
[TBL] [Abstract][Full Text] [Related]
10. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
11. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
12. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
13. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Blonde L; Montanya E
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
[TBL] [Abstract][Full Text] [Related]
14. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
15. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.
Wu S; Sun F; Zhang Y; Yang Z; Hong T; Chen Y; Zhan S
J Clin Pharm Ther; 2014 Feb; 39(1):7-13. PubMed ID: 24127768
[TBL] [Abstract][Full Text] [Related]
16. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
17. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
18. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.
Peng H; Want LL; Aroda VR
Curr Diab Rep; 2016 May; 16(5):44. PubMed ID: 27037706
[TBL] [Abstract][Full Text] [Related]
19. [Extrapancreatic effects of GLP-1 receptor agonists: an open window towards new treatment goals in type 2 diabetes].
Salvador J; Andrada P
Med Clin (Barc); 2014 Sep; 143 Suppl 2():28-34. PubMed ID: 25437463
[TBL] [Abstract][Full Text] [Related]
20. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
Bode B
Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
